BNP Paribas Financial Markets
ABCL icon

BNP Paribas Financial Markets’s AbCellera Biologics ABCL Stock Holding History

BNP Paribas Financial Markets’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$67.3K Sell
8,575
-116,747
-93% -$571K ﹤0.01% 4744
2026
Q1 		$437K Sell
125,322
-85,959
-41% -$309K ﹤0.01% 3660
2025
Q4 		$723K Buy
211,281
+64,504
+44% +$288K ﹤0.01% 3340
2025
Q3 		$738K Buy
146,777
+140,917
+2,405% +$621K ﹤0.01% 3341
2025
Q2 		$20.1K Buy
5,860
+1,428
+32% +$3.56K ﹤0.01% 4604
2025
Q1 		$9.88K Sell
4,432
-294
-6% -$843 ﹤0.01% 4721
2024
Q4 		$13.8K Buy
+4,726
New +$13.2K ﹤0.01% 4793

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

BNP Paribas Financial Markets's ABCL Position: Q2 2026 in Review

BNP Paribas Financial Markets reduced its AbCellera Biologics (ABCL) stake by 93% in Q2 2026, selling an estimated $571K and leaving 8,575 shares worth $67.3K. The position accounts for ﹤0.01% of the portfolio, ranked #4744.

BNP Paribas Financial Markets first reported a position in ABCL in Q4 2024 and has held it in 7 quarters since. The position peaked at $738K in Q3 2025. 150 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

  • BNP Paribas Financial Markets held 8,575 shares of AbCellera Biologics worth $67.3K as of Q2 2026.
  • BNP Paribas Financial Markets sold 116,747 AbCellera Biologics shares in Q2 2026, an estimated $571K.
  • AbCellera Biologics made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #4744 holding.
  • BNP Paribas Financial Markets first reported a position in AbCellera Biologics in Q4 2024 and has held it in 7 quarters since.
  • BNP Paribas Financial Markets's AbCellera Biologics position peaked at $738K in Q3 2025.
  • 150 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.